News & Updates

The phase III CROWN trial previously showed that first-line treatment with lorlatinib, a third-generation ALK tyrosine kinase inhibitor (TKI), provided significant survival benefits vs crizotinib in patients with treatment-naïve, advanced, ALK-positive non-small-cell lung cancer (NSCLC). At the 2024 World Conference on Lung Cancer, CROWN investigators discussed the patterns of progression and management of adverse events (AEs) associated with lorlatinib after 5 years of follow-up.

Treatment with methylnaltrexone, a peripherally acting µ-opioid receptor antagonist, does not significantly reduce the severity of acute pancreatitis (AP) relative to placebo, a study has shown.

Older-generation generic antiobesity medications (AOMs) for weight maintenance may be prescribed to patients who have achieved successful weight loss with glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, suggests a study.

Data presented at APSR 2024 demonstrate the ability of glucagon-like peptide 1 receptor agonists (GLP1-RAs) to benefit obese individuals with asthma.